Skip to main content

FDA grants designation to Insmed

The Food and Drug Administration granted Breakthrough Therapy Designation to Insmed Inc.’s (Nasdaq: INSM) nontuberculous mycobacterial lung disease treatment Arikayce/Arikace. Shares of the biopharmaceutical leaped $4.83 to $17.30.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.